Home Stock

Stock Research: Chunghwa Chemical Synthesis & Biotech

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Chunghwa Chemical Synthesis & Biotech

TAI:1762 TW0001762003
49
  • Value
    35
  • Growth
    77
  • Safety
    Safety
    28
  • Combined
    38
  • Sentiment
    53
  • 360° View
    360° View
    49
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company manufacturing and distributing biotechnology and chemical synthetic products. The company's main businesses include biotechnology products (e.g., pravastatin, rapamycin, tacrolimus) and non-biotechnology products (e.g., methocarbamol, guaifenesin), applied in drugs for various treatments including cough, diabetes, cardiovascular diseases, high blood pressure, and immune system diseases. It operates in domestic and overseas markets, including Asia, the Americas, and Europe. In the last fiscal year, the company had a market cap of $73 million, profits of $12 million, and revenue of $41 million.

more

ANALYSIS: With an Obermatt 360° View of 28 (better than 28% compared with alternatives), overall professional sentiment and financial characteristics for the stock Chunghwa Chemical Synthesis & Biotech are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Chunghwa Chemical Synthesis & Biotech. The consolidated Growth Rank has a good rank of 67, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 67% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 34 means that the share price of Chunghwa Chemical Synthesis & Biotech is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 66% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 28, which means that the company has a riskier financing structure than 72% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 43, indicating professional investors are more pessimistic about the stock than for 57% of alternative investment opportunities. ...read more

more
Strongest Rank Analyst Opinions
Weakest Rank Revenue Growth
Country Taiwan
Industry Pharmaceuticals
Size X-Small
Website ccsb.com.tw
Index
Chunghwa Chemical Synthesis & Biotech stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
35 54 80 73
Growth
77 14 47 100
Safety
Safety
28 38 61 72
Sentiment
53 70 41 100
360° View
360° View
49 38 64 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
1 20 20 97
Opinions Change
50 50 50 50
Pro Holdings
n/a 52 30 98
Market Pulse
28 91 100 100
Sentiment
53 70 41 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
35 54 80 73
Growth
77 14 47 100
Safety Safety
28 38 61 72
Combined
38 13 79 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
28 51 57 63
Price vs. Earnings (P/E)
1 26 97 95
Price vs. Book (P/B)
69 83 65 63
Dividend Yield
1 64 67 65
Value
35 54 80 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
98 22 67 98
Profit Growth
20 28 15 26
Capital Growth
50 54 81 96
Stock Returns
66 16 39 91
Growth
77 14 47 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
59 33 47 94
Refinancing
53 63 57 27
Liquidity
12 31 61 61
Safety Safety
28 38 61 72

Similar Stocks

Discover high‑ranked alternatives to Chunghwa Chemical Synthesis & Biotech and broaden your portfolio horizons.

Tripod Technology

TAI:3044
Country: Taiwan
Industry: Electronic Components
Size: Medium
Full Stock Analysis

WPG

TAI:3702
Country: Taiwan
Industry: Technology Distributors
Size: Large
Full Stock Analysis

Nippon Shinyaku

TYO:4516
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Tsumura

TYO:4540
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The only positive is high growth. The stock is expensive (low Value Rank), risky to finance, and carries critical professional sentiment. This is a risky proposition. Avoid unless you have exceptional conviction that the growth alone will overcome the price and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews